• Janssen files EGFR-targeting antibody amivantamab with EMA pharmatimes
    January 05, 2021
    Janssen, the pharmaceutical division of Johnson & Johnson, has submitted a marketing authorisation application to the European Medicines Agency (EMA) for approval of its epidermal growth factor receptor (EGFR)-targeting bispecific antibody amivantamab.
  • Janssen Submits BLA for Metastatic Lung Cancer Treatment americanpharmaceuticalreview
    December 24, 2020
  • Janssen eyes US approval for EGFR-targeting NSCLC therapy pharmatimes
    December 08, 2020
  • Janssen Announces Phase 1 Results for Amivantamab for Advanced NSCLC americanpharmaceuticalreview
    May 21, 2020
    The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the Phase 1 CHRYSALIS study.
PharmaSources Customer Service